Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy

Neuro-Oncology

Volumn 15, Issue 3, 2013, Pages 382-390

  Ellingson, Benjamin M ^a   Cloughesy, Timothy F ^a   Lai, Albert ^a   Nghiemphu, Phioanh L ^a   Liau, Linda M ^a   Pope, Whitney B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

diffusion MRI; fDM; functional diffusion map; glioblastoma

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE; TEMOZOLOMIDE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTRAST ENHANCEMENT; EXTERNAL BEAM RADIOTHERAPY; FUNCTIONAL DIFFUSION MAPPING; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; MAJOR CLINICAL STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DIFFUSION MAGNETIC RESONANCE IMAGING; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; SURVIVAL RATE;

EID: 84874548673     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos314     Document Type: Article

References (37)

1. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 1999;9:53-60. (Pubitemid 29068231)
2. Lyng H, Haraldseth O, Rofstad EK. Measurements of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med. 2000;43(6):828-836. (Pubitemid 30387603)
3. Ellingson BM, Malkin MG, Rand SD, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010;31(3):538-548.
4. Provenzale JM, Mukundan S, Barboriak DP. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology. 2006;239(3):632-649. (Pubitemid 43830599)
5. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker for therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92(24):2029-2036. (Pubitemid 32045900)
6. Ellingson BM, Cloughesy TF, Zaw T, et al. Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2012;14(3):333-343.
7. Ellingson BM, Malkin MG, Rand SD, Bedekar DP, Schmainda KM. Functional diffusion maps applied to FLAIR abnormal areas are valuable for the clinical monitoring of recurrent brain tumors. Proc Intl Soc Mag Reson Med. 2009;17:285.
8. Ellingson BM, Malkin MG, Rand SD, et al. Functional diffusion maps (fDMs) applied to FLAIR abnormal regions can detect pseudoprogression from recurrent tumor in malignant glioma. Proc Intl Soc Mag Reson Med. 2010;18:621.
9. Ellingson BM, Malkin MG, Rand SD, et al. Comparison of cytotoxic and anti-angiogenic treatment responses using functional diffusion maps in FLAIR abnormal regions. Proc Intl Soc Mag Reson Med. 2009;17:1010.
10. Ellingson BM, Rand SD, Malkin MG, Schmainda KM. Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri. J Neurooncol. 2010;97(3):419-423.
11. Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Nat Acad Sci. 2005;102(46):16759-16764. (Pubitemid 41688850)
12. Hamstra DA, Galbán CJ, Meyer CR, et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008;26(10):3387-3394.
13. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Nat Acad Sci. 2005;102(15):5524-5529. (Pubitemid 40530291)
14. Moffat BA, Chenevert TL, Meyer CR, et al. The functional diffusion map: An imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia. 2006;8(4):259-267.
15. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. Magn Reson Med. 2011;67(1):237-245.
16. Ellingson BM, Malkin MG, Rand SD, et al. Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol. 2011;102(1):95-103.
17. Reese TG, Heid O, Weisskoff RM, Wedeen VJ. Reduction of eddycurrent-induced distortion in diffusion MRI using a twice-refocused spin echo. Magn Reson Med. 2003;49(1):177-182. (Pubitemid 36042349)
18. Cox RW, Jesmanowicz A. Real-time 3D image registration for functional MRI. Magn Reson Med. 1999;42:1014-1018.
19. Ellingson BM, Malkin MG, Rand SD, et al. Volumetric analysis of functional diffusion maps (fDMs) is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol. 2011;102(1):95-103.
20. Earnest F, 4th, Kelly PJ, Scheithauer BW, et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology. 1988;166(3):823-827. (Pubitemid 18058950)
21. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 1987;66(6):865-874. (Pubitemid 17085708)
22. Kelly PJ, Daumas-Duport C, Scheithauer BW, Kall BA, Kispert DB. Stereotactic histological correlations of computed tomography-and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc. 1987;62(6):450-459. (Pubitemid 17084816)
23. Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology. 1992;34(6):463-469.
24. Brant-Zawadski M, Norman D, Newton TH. Magnetic resonance imaging of the brain: the optimal screening technique. Radiology. 1984;152:71-77. (Pubitemid 14083156)
25. Byrne TN. Imaging of gliomas. Semin Oncol. 1994;21:162-171. (Pubitemid 24125956)
26. Husstedt HW, Sickert M, Kö stler H, Haubitz B, Becker H. Diagnostic value of the fast-FLAIR sequence in MR imaging of intracranial tumors. Eur Radiol. 2000;10(5):745-752. (Pubitemid 30321084)
27. Tsuchiya K, Mizutani Y, Hachiya J. Preliminary evaluation of fluidattenuated inversion-recovery MR in the diagnosis of intracranial tumors. AJNR Am J Neuroradiol. 1996;17(6):1081-1086. (Pubitemid 26198514)
28. Essig M, Hawighorst H, Schoenberg SO, et al. Fast fluid-attenuated inversion-recovery (FLAIR) MRI in the assessment of intraaxial brain tumors. J Magn Reson Imaging. 1998;8(4):789-798. (Pubitemid 28357585)
29. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011;13(4):401-409.
30. Ellingson BM, LaViolette PS, Rand SD, et al. Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI. Magn Reson Med. 2011;65(4):1131-1143.
31. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2011;105(1):91-101.
32. Galban CJ, Chenevert TL, Meyer CR, et al. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med. 2009;15(5):572-576.
33. Ellingson BM, Cloughesy TF, Lai A, et al. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2012;106(1):111-119.
34. Ellingson BM, Bedekar DP, Malkin MG, et al. Hybrid functional diffusion and perfusion maps for evaluation of gliomas. Proc Intl Soc Mag Reson Med. 2009;17:1000.
35. Ellingson BM, Cloughesy TF, Lai A, et al. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011;13(10):1151-1161.
36. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11(2):102-125.
37. Sheerin F, Pretorius PM, Briley D, Meagher T. Differential diagnosis of restricted diffusion confined to the cerebral cortex. Clin Radiol. 2008;63(11):1245-1253.